<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01397240</url>
  </required_header>
  <id_info>
    <org_study_id>DW_ABS002P</org_study_id>
    <nct_id>NCT01397240</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Albis速: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients</brief_title>
  <acronym>AL-PA</acronym>
  <official_title>The Safety and Efficacy of Albis速: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients Taking Low-dose Aspirin, A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to research the safety and efficacy of Albis速 for the prevention
      of aspirin-induced gastrointestinal ulcers in patients taking low-dose aspirin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Safety and Efficacy of Albis速: The Prevention of Aspirin-induced Gastrointestinal Ulcers
      in Patients taking Low-dose Aspirin, A pilot study Double-Blind, Placebo-Controlled,
      Randomized, Multicenter, Parallel, Prospective study
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of Gastric Ulcer</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of gastiritis</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Patients Taking Low-dose Aspirin</condition>
  <arm_group>
    <arm_group_label>Albis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Albis Tab 2 tab, twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 2 tab, twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albis Tab</intervention_name>
    <description>2 Tab, twice a day, 12 weeks</description>
    <arm_group_label>Albis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 Tab, twice a day, 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 20 to 80 years

          -  Subjects identified with at least one of the following diagnosis (Angina, Myocardial
             Infarction(Old), Cerebrovascular Disease, Peripheral Vascular Disease, Diabetes,
             Hypertension, Hypercholeseterolemia, Obesity) who are required to take a low dose of
             Aspirin (100mg/day) for more than 12 weeks.

        Exclusion Criteria:

          -  Females who are pregnant, nursing, or planning a pregnancy during the study period or
             females of childbearing potential

          -  Peptic ulcer or Reflux oesophagitis

          -  hemostatic disorder or coagulation disorder

          -  Known allergy or hypersensitivity to the study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo Jin Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangnam Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyo Jin Park</last_name>
    <phone>82-2-2019-3318</phone>
    <email>hjpark21@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gangnam severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2011</study_first_submitted>
  <study_first_submitted_qc>July 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2011</study_first_posted>
  <last_update_submitted>January 8, 2012</last_update_submitted>
  <last_update_submitted_qc>January 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

